Posted by SLS on June 19, 2019, at 14:23:07
In reply to Solriamfetol (new DNRI for wakefulness) avail July, posted by PeterMartin on June 19, 2019, at 11:08:07
Thanks!
- Scott
> Just a heads up that "Sonosi" (Jazz pharma's solriamfetol) just received it's class scheduling (IV) and will be available in early July. I bet it'll be extremely expensive but hopefully there'll be samples to try. I'd love to hear from anyone who gives it a go. It's only currently approved for narcolepsy but it's being tried for other conditions.
>
> https://www.empr.com/home/news/wakefulness-promoter-sunosi-designated-schedule-iv-controlled-substance/
>
> "Sunosi, a first-in-class dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), was approved in March 2019 to improve wakefulness in adult patients with excessive daytime sleepiness "
>
> "Sunosi is expected to be available in 75mg (functionally scored) and 150mg tablets in early July. "Some see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1104910
URL: http://www.dr-bob.org/babble/20190513/msgs/1104911.html